

Ghady Haidar

List of Publications by Year in descending order

Source: <https://exaly.com/author-pdf/7484705/publications.pdf>

Version: 2024-02-01

56
papers

3,104
citations

257357

24
h-index

175177

52
g-index

59
all docs

59
docs citations

59
times ranked

5408
citing authors

#	ARTICLE	IF	CITATIONS
1	Recurrent deletions in the SARS-CoV-2 spike glycoprotein drive antibody escape. <i>Science</i> , 2021, 371, 1139-1142.	6.0	475
2	Clinical Outcomes, Drug Toxicity, and Emergence of Ceftazidime-Avibactam Resistance Among Patients Treated for Carbapenem-Resistant Enterobacteriaceae Infections: Table 1.. <i>Clinical Infectious Diseases</i> , 2016, 63, 1615-1618.	2.9	362
3	Coronavirus Disease 2019 in Solid Organ Transplant: A Multicenter Cohort Study. <i>Clinical Infectious Diseases</i> , 2021, 73, e4090-e4099.	2.9	332
4	Ceftolozane-Tazobactam for the Treatment of Multidrug-Resistant <i>Pseudomonas aeruginosa</i> Infections: Clinical Effectiveness and Evolution of Resistance. <i>Clinical Infectious Diseases</i> , 2017, 65, 110-120.	2.9	224
5	Mutations in <i>bla</i> _{KPC-3} That Confer Ceftazidime-Avibactam Resistance Encode Novel KPC-3 Variants That Function as Extended-Spectrum β -Lactamases. <i>Antimicrobial Agents and Chemotherapy</i> , 2017, 61, .	1.4	154
6	Identifying Spectra of Activity and Therapeutic Niches for Ceftazidime-Avibactam and Imipenem-Relebactam against Carbapenem-Resistant Enterobacteriaceae. <i>Antimicrobial Agents and Chemotherapy</i> , 2017, 61, .	1.4	122
7	Intractable Coronavirus Disease 2019 (COVID-19) and Prolonged Severe Acute Respiratory Syndrome Coronavirus 2 (SARS-CoV-2) Replication in a Chimeric Antigen Receptor-Modified T-Cell Therapy Recipient: A Case Study. <i>Clinical Infectious Diseases</i> , 2021, 73, e815-e821.	2.9	113
8	Phage Therapy of <i>Mycobacterium</i> Infections: Compassionate Use of Phages in 20 Patients With Drug-Resistant Mycobacterial Disease. <i>Clinical Infectious Diseases</i> , 2023, 76, 103-112.	2.9	109
9	Suboptimal Response to Coronavirus Disease 2019 Messenger RNA Vaccines in Patients With Hematologic Malignancies: A Need for Vigilance in the Postmasking Era. <i>Open Forum Infectious Diseases</i> , 2021, 8, ofab353.	0.4	99
10	Severe Acute Respiratory Syndrome Coronavirus 2 Viremia Is Associated With Coronavirus Disease 2019 Severity and Predicts Clinical Outcomes. <i>Clinical Infectious Diseases</i> , 2022, 74, 1525-1533.	2.9	96
11	Cytomegalovirus Infection in Solid Organ and Hematopoietic Cell Transplantation: State of the Evidence. <i>Journal of Infectious Diseases</i> , 2020, 221, S23-S31.	1.9	80
12	Invasive Mold Infections After Chimeric Antigen Receptor-Modified T-Cell Therapy: A Case Series, Review of the Literature, and Implications for Prophylaxis. <i>Clinical Infectious Diseases</i> , 2020, 71, 672-676.	2.9	65
13	Prospective Evaluation of Coronavirus Disease 2019 (COVID-19) Vaccine Responses Across a Broad Spectrum of Immunocompromising Conditions: the COVID-19 Vaccination in the Immunocompromised Study (COVICS). <i>Clinical Infectious Diseases</i> , 2022, 75, e630-e644.	2.9	65
14	Viral infections in solid organ transplant recipients: novel updates and a review of the classics. <i>Current Opinion in Infectious Diseases</i> , 2017, 30, 579-588.	1.3	59
15	Impact of Bamlanivimab Monoclonal Antibody Treatment on Hospitalization and Mortality Among Nonhospitalized Adults With Severe Acute Respiratory Syndrome Coronavirus 2 Infection. <i>Open Forum Infectious Diseases</i> , 2021, 8, ofab254.	0.4	59
16	Fever of Unknown Origin. <i>New England Journal of Medicine</i> , 2022, 386, 463-477.	18.9	57
17	Verification of Ceftazidime-Avibactam and Ceftolozane-Tazobactam Susceptibility Testing Methods against Carbapenem-Resistant Enterobacteriaceae and <i>Pseudomonas aeruginosa</i> . <i>Journal of Clinical Microbiology</i> , 2018, 56, .	1.8	55
18	Improving the Outcomes of Immunocompromised Patients With Coronavirus Disease 2019. <i>Clinical Infectious Diseases</i> , 2021, 73, e1397-e1401.	2.9	44

#	ARTICLE	IF	CITATIONS
19	COVID-19: Challenges of Viral Variants. Annual Review of Medicine, 2023, 74, 31-53.	5.0	43
20	Association between the Presence of Aminoglycoside-Modifying Enzymes and <i>In Vitro</i> Activity of Gentamicin, Tobramycin, Amikacin, and Plazomicin against <i>Klebsiella pneumoniae</i> Carbapenemase- and Extended-Spectrum- β -Lactamase-Producing Enterobacter Species. Antimicrobial Agents and Chemotherapy, 2016, 60, 5208-5214.	1.4	38
21	Heart or lung transplant outcomes in HIV-infected recipients. Journal of Heart and Lung Transplantation, 2019, 38, 1296-1305.	0.3	37
22	Effectiveness of Casirivimab-Imdevimab and Sotrovimab During a SARS-CoV-2 Delta Variant Surge. JAMA Network Open, 2022, 5, e2220957.	2.8	37
23	<i>In Vitro</i> Susceptibility of Multidrug-Resistant <i>Pseudomonas aeruginosa</i> following Treatment-Emergent Resistance to Ceftolozane-Tazobactam. Antimicrobial Agents and Chemotherapy, 2021, 65, .	1.4	31
24	<i>Phellinus</i> species: An emerging cause of refractory fungal infections in patients with χ^2 linked chronic granulomatous disease. Mycoses, 2017, 60, 155-160.	1.8	30
25	Invasive Fungal Infections after Anti-CD19 Chimeric Antigen Receptor-Modified T-Cell Therapy: State of the Evidence and Future Directions. Journal of Fungi (Basel, Switzerland), 2021, 7, 156.	1.5	25
26	Intraabdominal infections in solid organ transplant recipients: Guidelines from the American Society of Transplantation Infectious Diseases Community of Practice. Clinical Transplantation, 2019, 33, e13595.	0.8	22
27	Infections after anti-CD19 chimeric antigen receptor T-cell therapy for hematologic malignancies: timeline, prevention, and uncertainties. Current Opinion in Infectious Diseases, 2020, 33, 449-457.	1.3	21
28	The UPMC OPTIMISE-C19 (Optimizing Treatment and Impact of Monoclonal antibodies through) Tj ETQq0 0 0 rgBT /Overlock 10 Tf 50 3 comparative effectiveness platform trial with response-adaptive randomization. Trials, 2021, 22, 363.	0.7	20
29	Rasamsonia sp: An emerging infection amongst chronic granulomatous disease patients. A case of disseminated infection by a putatively novel Rasamsonia argillacea species complex involving the heart. Medical Mycology Case Reports, 2019, 24, 54-57.	0.7	13
30	Clarifying the HOPE Act landscape: The challenge of donors with false-positive HIV results. American Journal of Transplantation, 2020, 20, 617-619.	2.6	13
31	Brief Report: Willingness to Accept HIV-Infected and Increased Infectious Risk Donor Organs Among Transplant Candidates Living With HIV. Journal of Acquired Immune Deficiency Syndromes (1999), 2020, 85, 88-92.	0.9	13
32	The Times, They are a-Changing. Transplantation, 2017, 101, 1987-1995.	0.5	11
33	Launching a comparative effectiveness adaptive platform trial of monoclonal antibodies for COVID-19 in 21 days. Contemporary Clinical Trials, 2022, 113, 106652.	0.8	11
34	Invasive Tracheobronchial Aspergillosis in a Lung Transplant Recipient Receiving Belatacept as Salvage Maintenance Immunosuppression: A Case Report. Transplantation Proceedings, 2016, 48, 275-278.	0.3	10
35	Circulating microbial cell-free DNA is associated with inflammatory host-responses in severe pneumonia. Thorax, 2021, 76, 1231-1235.	2.7	10
36	How We Approach Combination Antifungal Therapy for Invasive Aspergillosis and Mucormycosis in Transplant Recipients. Transplantation, 2018, 102, 1815-1823.	0.5	8

#	ARTICLE	IF	CITATIONS
37	Cryptococcus: Shedding New Light on an Inveterate Yeast. <i>Journal of Fungi</i> (Basel, Switzerland), 2015, 1, 115-129.	1.5	7
38	Preprocedural SARS-CoV-2 Testing to Sustain Medically Needed Health Care Delivery During the COVID-19 Pandemic: A Prospective Observational Study. <i>Open Forum Infectious Diseases</i> , 2021, 8, ofab022.	0.4	7
39	National Landscape of Human Immunodeficiency Virus–Positive Deceased Organ Donors in the United States. <i>Clinical Infectious Diseases</i> , 2022, 74, 2010-2019.	2.9	7
40	A case of immune reconstitution syndrome complicating progressive multifocal leukoencephalopathy after kidney transplant: Clinical, pathological, and radiographic features. <i>Transplant Infectious Disease</i> , 2019, 21, e13162.	0.7	5
41	Successful lung transplantation from a hepatitis C RNA–positive donor to a hepatitis C treatment–experienced recipient with cystic fibrosis. <i>Journal of Thoracic and Cardiovascular Surgery</i> , 2019, 158, e155-e157.	0.4	5
42	Diagnostic Modalities for Invasive Mould Infections among Hematopoietic Stem Cell Transplant and Solid Organ Recipients: Performance Characteristics and Practical Roles in the Clinic. <i>Journal of Fungi</i> (Basel, Switzerland), 2015, 1, 252-276.	1.5	4
43	The Evolving Challenge of Infections in Cirrhosis. <i>New England Journal of Medicine</i> , 2021, 385, 1150-1152.	13.9	4
44	Daptomycin-Resistant <i>Enterococcus</i> Bacteremia Is Associated With Prior Daptomycin Use and Increased Mortality After Liver Transplantation. <i>Open Forum Infectious Diseases</i> , 2022, 9, ofab659.	0.4	4
45	Reply to Lewis and Kontoyiannis. <i>Clinical Infectious Diseases</i> , 2020, 71, 1803-1804.	2.9	3
46	1105. The Burden of Infections Prior to Chimeric Antigen Receptor (CAR) Modified T-cell Therapy Predicts Post-CAR T-cell Infectious Complications. <i>Open Forum Infectious Diseases</i> , 2020, 7, S583-S583.	0.4	3
47	Immunity to a third BNT162B2 COVID-19 vaccine after heart transplantation: bridging the knowledge gap to end the pandemic for organ transplant recipients. <i>Journal of Heart and Lung Transplantation</i> , 2022, , .	0.3	3
48	Improving the outcomes of human immunodeficiency virus/hepatitis C virus–coinfected transplant recipients: The answer is Blowin™ in the wind. <i>Liver Transplantation</i> , 2017, 23, 727-729.	1.3	1
49	2438. Ceftolozane/Tazobactam (C/T) Against Multidrug-Resistant <i>Pseudomonas aeruginosa</i> (MDR-Pa) Infections: Clinical Efficacy, and Baseline and Emergent Resistance. <i>Open Forum Infectious Diseases</i> , 2018, 5, S729-S729.	0.4	1
50	245. Plasma and Respiratory Specimen Metagenomic Sequencing for the Diagnosis of Severe Pneumonia in Mechanically-Ventilated Patients. <i>Open Forum Infectious Diseases</i> , 2019, 6, S138-S138.	0.4	1
51	Coronavirus Disease 2019 (COVID-19), Organ Transplantation, and the Nuances of Immunomodulation: Lessons Learned and What Comes Next. <i>Clinical Infectious Diseases</i> , 2020, 73, e4100-e4102.	2.9	1
52	Pediatric SARS-CoV-2 seroprevalence during mitigation procedures in Southwestern Pennsylvania. <i>Journal of Clinical Virology Plus</i> , 2021, 1, 100026.	0.4	1
53	Therapeutic Drug Monitoring (TDM) of Suspension (SUS), Extended-Release (ER), and Intravenous (IV) Posaconazole (POS) at a Large Transplant Center. <i>Open Forum Infectious Diseases</i> , 2017, 4, S297-S297.	0.4	0
54	555. Effectiveness of a Treatment Team on Adherence to Health System Guidelines for Hydroxychloroquine Use During Two Phases of the COVID-19 Epidemic. <i>Open Forum Infectious Diseases</i> , 2020, 7, S343-S343.	0.4	0

#	ARTICLE	IF	CITATIONS
55	896. Examining the Impact of the COVID-19 Pandemic on Delivery of HIV Care and Prevention Services Among Patients in a Ryan White Clinic. <i>Open Forum Infectious Diseases</i> , 2021, 8, S539-S539.	0.4	0
56	202. The Impact and Safety of Discontinuing Routine Surveillance Blood Culture Monitoring in Allogeneic Hematopoietic Cell Transplant Recipients. <i>Open Forum Infectious Diseases</i> , 2021, 8, S209-S209.	0.4	0